Aurigene Pharmaceutical Services Limited, a contract research, development, and manufacturing services organization (CDMO) and a step-down subsidiary of Dr. Reddy’s Laboratories announced the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors. The building is expected to be fully operational in first half of 2024.

As a first step, Aurigene is investing $40 million in an R&D and pilot scale facility at Genome Valley, a Biotechnology Park in Hyderabad. The facility will provide process development and clinical supply services for global biotech companies and is based on a state-of-the-art design concept, allowing maximum flexibility for a multi-product, multi-platform offering across therapeutic proteins, antibodies, and viral vectors.

In addition, the expansion provides global customers access to a dedicated team and modern labs, including a pilot facility. This offer is complemented by exclusive access to an established large-scale GMP manufacturing facility with a drug substance capacity of 15kl and fill-finish capabilities making it possible to provide commercial quantities seamlessly. An additional fill-finish line is also under construction to be validated before the end of 2024. 

Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd., said, “We see an increased outsourcing demand from global biopharmaceutical companies. With this expansion in biotherapeutics CDMO, we will be positioned to provide integrated services from clinical research to commercial manufacturing for small and large molecules. Investing in emerging technologies and health solutions reinforces our aim to triple our existing reach to touch over 1.5 billion patients worldwide by 2030. “

Jayanth Sridhar, global head of biologics, Dr. Reddy’s Laboratories Ltd.  said, “We are excited to expand our infrastructure in Hyderabad in our continuous efforts towards providing world class services to biotech companies worldwide. Our experience and fully integrated setup in developing biosimilars end to end, right from cell line development to process development, to scale up and commercial manufacturing for drug substance and drug product, provides us with comprehensive capabilities to offer fast solutions for our potential customers and clients. We wish to work with our customers in a variety of modalities and technologies to address the most pressing unmet needs.”